At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 6 enrolled
Drug / intervention
cis-diamminedichloroplatinumdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Trial of Intratumoral Cisplatin for Early Stage, Resectable, Non-Small Cell Lung Cancer
In Brief
A Phase 1 clinical trial evaluating cis-diamminedichloroplatinum for Non-Small Cell Lung Cancer. Completed, enrolled 6 participants across 1 site.
Detailed Summary
PRIMARY OBJECTIVE: To identify the maximum tolerated dose (MTD) of intratumoral cisplatin, delivered during a single bronchoscopy with cone-beam CT confirmation, in a dose escalation protocol DESIGN: 3+3 dose escalation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small Cell Lung Cancer
CountriesUnited States
CollaboratorsJohnson & Johnson
Timeline
Phase 1CompletedFinished
20222023202420252026
Enrollment StartMar 2021
First PostedMar 2021
Primary CompletionOct 2025
TodayJul 2026
First PostedMar 22, 2021
Enrollment StartMar 8, 2021
Primary CompletionOct 1, 2025
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 5.3 years ago
Interventions
cis-diamminedichloroplatinumdrug
Cisplatin delivered bronchoscopically at the time of diagnosis of NSCLC